VERV Nov 2024 2.500 put
- GlobeNewswire
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its board of directors. Dr. Tatsis currently serves as executive vice president, chief regulatory and quality officer, of Vertex Pharmaceuticals. Ms. Morrison currently serves as chief executive officer and director
- Simply Wall St.
One Verve Therapeutics Insider Raised Stake By 29% In Previous Year
Viewing insider transactions for Verve Therapeutics, Inc.'s ( NASDAQ:VERV ) over the last year, we see that insiders...
- GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on May 31, 2024, the company granted equity awards to four new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c
